Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trans-resveratrol oral - Jupiter Neurosciences

Next Previous
Drug Profile

Trans-resveratrol oral - Jupiter Neurosciences

Alternative Names: JNS 101; JNS 102; JNS 107; JNS 108; JNS 109; JNS 110; JNS 120; JOT-101; JOTROL​

Latest Information Update: 28 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jupiter Orphan Therapeutics
  • Developer Jupiter Neurosciences; Mayo Clinic; Murdoch Childrens Research Institute; Universidade de Coimbra
  • Class Antidementias; Antineoplastics; Antithrombotics; Cardiovascular therapies; Neuroprotectants; Nonsteroidal anti-inflammatories; Phenols; Small molecules; Stilbenes; Vasodilators
  • Mechanism of Action Angiogenesis inhibitors; Antioxidants; Platelet aggregation inhibitors; Ribonucleotide reductase inhibitors; SIRT1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Friedreich's ataxia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Friedreich's ataxia; Mild cognitive impairment
  • Phase I MELAS syndrome; Mucopolysaccharidosis I
  • Preclinical Amyotrophic lateral sclerosis; COVID 2019 infections; Parkinson's disease; Traumatic brain injuries
  • Discontinued Pancreatic cancer; Spinocerebellar degeneration

Most Recent Events

  • 28 Apr 2023 Phase-I development in MELAS syndrome is ongoing in USA (PO) (Jupiter Neurosciences pipeline, April 2023)
  • 28 Apr 2023 Phase-I development in Mucopolysaccharidosis I is ongoing in USA (PO) (Jupiter Neurosciences pipeline, April 2023)
  • 28 Apr 2023 Phase-II clinical trials in Mild cognitive impairment in USA (PO) before April 2023 (Jupiter Neurosciences pipeline, April 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top